Treatment with gefitinib or erlotinib, a first-generation EGFR-TKI, often used in NSCLC treatment, can cause lung metastasis inhibition and the inhibited phosphorylation of EGFR in LLC1 cells treated with radiotherapy and LLC1-bearing tumors [20,21,22]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.